Ferroptosis & Inflammation

The Ferroptosis & Inflammation platform is based on a family of enzyme targets – oxidoreductases – which are critical to the generation and regulation of energy that are key to disease pathology in the central nervous system (CNS) and other organ systems. The platform utilizes expertise in electron-transfer chemistry to modulate key biological processes beyond the reach of current drug development approaches. ​​

Ferroptosis is a form of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides. It is genetically and biochemically distinct from other forms of regulated cell death such as apoptosis. ​​

The process of ferroptosis causes certain cell types that participate in the innate and adaptive immune response to become activated and produce pro-inflammatory cytokines. At PTC, we have grouped ferroptosis and inflammation into one platform because a hallmark of ferroptosis that is understood to cause cell death and disease progression is inflammation. ​​

Several of our current programs are targeting neuroinflammation—a critical aspect of disease pathology in neurodegenerative diseases. Specifically, our compounds are designed to prevent activation of pro-inflammatory glial cells and astrocytes. PTC have a number of development-stage products that were discovered using the ferroptosis and inflammation platform.​